Hydrogen Sulfide as a Novel Regulatory Factor in Liver Health and Disease

1School of Basic Medical Sciences, Henan University, Kaifeng, Henan 475004, China
2Henan International Joint Laboratory for Nuclear Protein Regulation, Henan University, Kaifeng, Henan 475004, China
3The First Affiliated Hospital of Henan University, Kaifeng, Henan 475001, China
4Center for Precision Medicine, Zhengzhou University, Zhengzhou, Henan 450052, China
5Institute for Innovative Drug Design and Evaluation, School of Pharmacy, Henan University, Kaifeng, Henan 475004, China

Correspondence should be addressed to Shao-Feng Duan; sduan@henu.edu.cn and Xin-Ying Ji; 10190096@vip.henu.edu.cn

Received 25 July 2018; Accepted 29 November 2018; Published 20 January 2019

Copyright © 2019 Dong-Dong Wu et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Hydrogen sulfide (H₂S), a colorless gas smelling of rotten egg, has long been recognized as a toxic gas and environment pollutant. However, increasing evidence suggests that H₂S acts as a novel gasotransmitter and plays important roles in a variety of physiological and pathological processes in mammals. H₂S is involved in many hepatic functions, including the regulation of oxidative stress, glucose and lipid metabolism, vasculature, mitochondrial function, differentiation, and circadian rhythm. In addition, H₂S contributes to the pathogenesis and treatment of a number of liver diseases, such as hepatic fibrosis, liver cirrhosis, liver cancer, hepatic ischemia/reperfusion injury, nonalcoholic fatty liver disease/nonalcoholic steatohepatitis, hepatotoxicity, and acute liver failure. In this review, the biosynthesis and metabolism of H₂S in the liver are summarized and the role and mechanism of H₂S in liver health and disease are further discussed.

1. Introduction

Hydrogen sulfide (H₂S) is a colorless and water-soluble gas with the characteristic foul odor of rotten egg [1–3]. At physiological pH, nearly two thirds of H₂S exists as H⁺ and hydro sulfide anion, which subsequently decomposes to H⁺ and sulfide ion [4]. In mammals, H₂S is produced from L-cysteine and L-homocysteine mainly by cystathionine γ-lyase (CSE) and cystathionine β-synthase (CBS). Both CSE and CBS are cytosolic enzymes [5, 6]. 3-Mercaptopyruvate sulfurtransferase (3-MST) acts in combination with cysteine aminotransferase (CAT) to produce H₂S from L-cysteine in the presence of α-ketoglutarate (αKG). 3-MST and CAT are located in the mitochondria and cytosol [3, 7]. Furthermore, a recent study has shown that D-amino acid oxidase could metabolize D-cysteine to an achiral α-ketoacid, 3-mercaptopyruvate (3-MP), which is further metabolized to H₂S by 3-MST in both kidney and brain [8].

H₂S has been considered the third gaseous signaling molecule that plays important regulatory roles in a number of physiologic conditions, such as angiogenesis [9], vasodilatation [10], and neuronal activity [11]. The liver, the largest solid organ in the body, plays a key role in glucose and lipid metabolism, antioxidant defense, and xenobiotic metabolism [12–14]. The liver is an important organ for H₂S production and its clearance [3, 15]. CSE, CBS, and 3-MST have been detected in the liver, and they contribute to liver production of H₂S to different extents [3, 12]. The production and catabolism of H₂S in the liver are shown in Figure 1. Hepatic H₂S is involved in mitochondrial biogenesis and bioenergetics, insulin sensitivity, lipoprotein synthesis, and glucose metabolism [12, 16, 17]. However, H₂S also contributes to the
Figure 1: A schematic illustration of the biosynthesis and metabolism of H₂S in the liver. (a) H₂S is enzymatically produced from L-cysteine and L-homocysteine by CSE and CBS. 3-MST acts in combination with CAT to produce H₂S from L-cysteine in the presence of αKG. (b) H₂S can be stored as acid-labile sulfur and bound sulfane sulfur. Catabolism of H₂S is thought to occur mainly via rhodanese, methylation, binding to hemoglobin, and mitochondrial oxidation. H₂S: hydrogen sulfide; CSE: cystathionine γ-lyase; CBS: cystathionine β-synthase; H₂O: water; NH₃: ammonia; αKG: α-ketoglutarate; L-Glu: L-glutamate; CAT: cysteine aminotransferase; 3-MST: 3-mercaptopyruvate sulfurtransferase; pH: potential of hydrogen; CH₃-S-CH₃: dimethyl sulfide; CH₃-SH: methanethiol; S₂O₃²⁻: thiosulfate; SO₄²⁻: sulfate.
pathogenesis and treatment of many liver diseases, such as liver cirrhosis [18], liver cancer [19], hepatic fibrosis [20], hepatic ischemia/reperfusion (I/R) injury [21], and nonalcoholic steatohepatitis (NASH) [22].

In the present review, we highlight recent studies that provide new insight into the biosynthesis and metabolism of H$_2$S in the liver and further discuss the role and mechanism of H$_2$S in liver health and disease.

2. H$_2$S in Hepatic Function

2.1. H$_2$S in Hepatic Oxidative Stress. Reactive oxygen species (ROS), the by-products of normal aerobic cellular metabolism, are considered to be important signaling molecules in many cellular processes, including cell adhesion, immune response, apoptosis, and cell survival and growth [23–25]. Oxidative stress means that an imbalance develops between ROS and antioxidant systems, which is implicated in liver cancer [26], fatty liver [22], liver failure [27], and hepatic ischemia/reperfusion [28].

It has been demonstrated that increased carbonyl formation is an indicator of oxidative stress [12]. The level of carbonyl formation in the liver of CBS-deficient mice is higher when compared to the control group [29], suggesting that CBS may play a role in reducing hepatic oxidative stress. Recent studies have shown that treatment with relatively low concentrations of H$_2$S donor (NaHS or Na$_2$S) could decrease ROS levels, lipid peroxidation, and cytochrome P450 2E1 (CYP2E1) activity and elevate glutathione (GSH) levels and antioxidative enzyme activities like superoxide dismutase, glutathione peroxidase, catalase, and glutathione S-transferase in hepatocytes [30–32]. It should be noted that administration of 500 μM NaHS could increase ROS formation through the inhibition of cytochrome c oxidase and the depletion of GSH in rat primary hepatocytes, which could lead to hepatotoxicity [33]. These results together indicate that relatively low levels of H$_2$S could protect against hepatic oxidative stress; however, relatively high concentrations of H$_2$S may exert opposite effects. A proper dose of H$_2$S should be adopted to avoid H$_2$S-induced cytotoxicity in normal liver cells when it is used for the treatment of liver diseases.

2.2. H$_2$S in Hepatic Glucose Metabolism. The liver is crucial for the maintenance of blood glucose homeostasis by uptake of glucose in the postprandial state and conversion to triglyceride and glycogen and by production of glucose in the postabsorptive state by gluconeogenesis and glycogenolysis [34, 35].

Defects in the mechanisms by which insulin and glucose regulate hepatic glycogen metabolism disrupt blood glucose homeostasis and lead to metabolic disorders such as diabetes [35, 36] and glycogen storage disease [37]. It has been shown that the CSE activity is lower in livers of type 1 diabetic rats and peripheral blood mononuclear cells of type 1 diabetic patients [38], indicating that H$_2$S is involved in glucose regulation [17, 39]. A recent study demonstrates that the rate of gluconeogenesis in CSE knockout mice is reduced, which can be reversed by administration of NaHS [40]. Similarly, incubation with NaHS impairs glucose uptake and glycogen storage via decreasing glucokinase activity and increasing gluconeogenesis through S-sulfhydration of pyruvate carboxylase in hepatocytes [16, 41]. These findings suggest that H$_2$S may be a potential target in the treatment of diabetes.

2.3. H$_2$S in Hepatic Lipid Metabolism. The liver is the main metabolic organ and plays an important role in fatty acid and cholesterol metabolism [42]. Hepatic lipid metabolism is orchestrated by a delicate interplay of hormones, transcription factors, nuclear receptors, and intracellular signaling pathways [43]. Excessive accumulation of fat in the liver disturbs its function and leads to the development of many liver diseases, such as NASH, liver cirrhosis, and liver cancer [44]. CBS deficiency in mice liver increases expression of genes induced by endoplasmic reticulum stress and genes that regulate the expression of enzymes required for cholesterol and fatty acid biosynthesis and uptake [45]. Another study indicates that the levels of triglyceride and nonesterified fatty acids are elevated and the activity of thiolase, a key enzyme in beta-oxidation of fatty acids, is decreased in the liver of CBS-deficiency mice [46]. It has been shown that the expression levels of CBS and CSE and the lipid peroxidation were increased in the liver of high-fat diet- (HFD-) fed mice [47]. In addition, tyrosol supplementation increases hepatic CSE and CBS expression and H$_2$S synthesis in HFD-fed mice, which is associated with the attenuation of HFD-induced hepatic lipid peroxidation [48].

A recent study has revealed that administration of NaHS decreases the accumulation of lipids such as total cholesterol and triglyceride through downregulation of fatty acid synthase and upregulation of carnitine palmitoyltransferase-I in the liver of HFD-induced obese mice [49]. S-Propargyl-cysteine (SPRC), a substrate for endogenous H$_2$S, could reduce the lipid content both in human hepatocellular carcinoma HepG2 cells and in the liver of mice with nonalcoholic fatty liver disease (NAFLD) [50]. These findings indicate that H$_2$S is involved in hepatic lipid metabolism and the underlying mechanisms are needed to be further investigated.

2.4. H$_2$S in Hepatic Vasculature. The liver has a complex system of vascular supply, including the inflow of oxygenated blood through the hepatic artery and deoxygenated blood through the portal vein, as well as the outflow of deoxygenated blood through the hepatic veins to the inferior vena cava [51]. Anatomical variations in hepatic artery are of importance to surgeons in planning effective therapeutic strategies for abdominal surgical procedures [52]. The hepatic artery is involved in the pathogenesis of several diseases, such as steatosis, thrombosis, aneurysm, and pseudoaneurysm [51]. H$_2$S plays a key role in vascular homeostasis during physiological and pathological conditions. H$_2$S-based therapy in vascular disease is a novel area of research [53]. H$_2$S acts as an autocrine mediator in regulation of the contraction of hepatic stellate cells (HSCs) and that a decreased expression of CSE in HSCs may lead to the increased intrahepatic resistance in rodent models of liver cirrhosis [18]. A recent study has shown that H$_2$S differentially contributes to the microcirculatory dysfunction in both systemic and hepatic microcirculations, which can be attributed to H$_2$S-induced...
differential vasoactive function on sinusoidal and presinusoidal sites within the liver [54]. Another study demonstrates that H₂S increases the hepatic arterial buffer capacity and mediates vasorelaxation of the hepatic artery through activation of KATP channels [55]. However, a vasoconstrictor action of H₂S on the hepatic sinusoid has been observed, which is different from the dilatory effect of H₂S in presinusoidal resistance vessels [56]. More efforts should be paid to validate the different effects of H₂S on hepatic vasculature.

2.5. H₂S in Hepatic Mitochondrial Function. Mitochondria are double-membrane organelles whose shape is instrumental to their function in many cellular processes [57]. The major role of mitochondria is to regulate the production of energy-rich molecules such as adenosine triphosphate [58]. Mitochondria play important roles in the metabolism of glucose, lipids, and protein in the liver [59]. Under normoxic conditions, the protein expression of CBS in liver mitochondria is at a low level. Hepatic ischemia/hypoxia results in the accumulation of CBS in mitochondria and increased H₂S production, which prevents hypoxia-induced mitochondrial ROS production and Ca²⁺-mediated cytochrome C release from mitochondria [60]. CSE-generated H₂S induces liver mitochondrial biogenesis, which can be attributed to the peroxisome proliferator-activated receptor-γ coactivator-1α and peroxisome proliferator-activated receptor-γ coactivator-related protein signaling in primary hepatocytes [61]. 3-MP, the substrate of the enzyme 3-MST, stimulates mitochondrial H₂S production and enhances hepatic mitochondrial electron transport and cellular bioenergetics at low concentration, while it inhibits cellular bioenergetics at a higher concentration. In addition, low concentration of H₂S induces a significant increase in hepatic mitochondrial function, while a higher concentration of H₂S is inhibitory [62]. These results indicate that endogenous H₂S plays a physiological role in the maintenance of mitochondrial electron transport and cellular bioenergetics. Considering that different concentrations of exogenous H₂S exert diverse effects on hepatic mitochondrial function, the proper dose range of exogenous H₂S should be confirmed to achieve optimal hepatic mitochondrial function.

2.6. H₂S in Hepatic Differentiation. A number of etiologies such as viral infections, toxic injury, and genetic or autoimmune disorders may cause severe liver dysfunction resulting in acute liver failure or chronic liver disease [63]. Liver transplantation is the primary method to treat acute liver failure and end-stage liver diseases. However, it is limited by numerous problems, including shortage of donor organs, high cost, and immune rejection [64]. To solve these problems, stem-cell-based therapeutic strategies have emerged as alternative options [63, 65]. A recent study indicates that physiological concentrations of H₂S could increase the ability of human tooth-pulp stem cells (HTPC) to undergo hepaticogenic differentiation [66]. Another study has revealed that H₂S increases hepatic differentiation of both HTPC and human bone marrow stem cells [67]. These cells may be suitable for generation of functionally useful hepatocytes and transplantation into model animals with liver diseases. Whether H₂S can play a role in hepatic differentiation of other types of cells needs to be further investigated.

2.7. H₂S in Hepatic Circadian Rhythm. The circadian clock system comprises peripheral clocks in peripheral tissues and a central clock located in the suprachiasmatic nucleus of the hypothalamus [68]. Peripheral clocks in the liver contribute to maintaining liver homeostasis, including the regulation of energy metabolism and the expression of enzymes controlling the absorption and metabolism of xenobiotics [69]. Clock dysfunction leads to the development of liver diseases such as fatty liver diseases, hepatitis, cirrhosis, and liver cancer, and these disorders also disrupt clock function [68, 70]. A recent study has shown that treatment with NaHS could maintain the circadian rhythm of clock gene in isolated liver cells. It is speculated that H₂S increases the activity of sirtuin 1 protein and changes the nicotinamide adenine dinucleotide +/− reduced form of nicotinamide adenine dinucleotide ratio in hepatocytes to maintain the rhythm of expression of circadian clock genes, which can prevent and treat lipid metabolism-related diseases caused by the biological clock disorders [71]. In light of the key role of H₂S in regulating hepatic circadian rhythm, further studies are needed to elucidate whether H₂S could relieve liver diseases through hepatic circadian rhythm.

2.8. Natural Sulfur-Containing Agents in Hepatic Function. Garlic (Allium sativum), a member of the lily family, has been widely used both as a foodstuff and a traditional medicine worldwide for many centuries [72–74]. Garlic oil, one of the garlic products, is usually prepared by steam distillation and has been shown to contain a number of organosulfur compounds, such as diallyl sulfide (DAS), diallyl disulfide (DADS), and diallyl trisulfide (DATS), which have been considered to be the major biological agents [75, 76]. It has been reported that DAS activates nuclear receptor CAR to induce the Sul1e1 gene in the mouse liver. Whether DAS can play a role in estradiol synthesis pathways, estradiol turnover, or expression/activity of SULT1E1 in other tissues/organs needs to be clarified [74]. Another study indicates that administration of DADS or DATS increases the activities of the phase II enzymes, quinone reductase and glutathione S-transferase, and antioxidative enzyme glutathione peroxidase in rat liver cytosol, suggesting that DADS/DATS could increase the detoxification and antioxidative effects of the liver [77]. Similarly, DADS and DATS have been shown to increase the activities of both GSH reductase and GSH S-transferase in rat livers [78]. Furthermore, a recent study has shown that aldehyde dehydrogenase activity can be inhibited in vivo in the rat liver after treatment with DATS [79]. These results together indicate that natural sulfur-containing agents may play important roles in the regulation of hepatic function. Recent studies have demonstrated that DATS, DADS, and DATS can act as H₂S donors [80, 81]. Whether the regulatory effects of DATS, DADS, and DATS are mediated by H₂S need to be further investigated.
3. **H$_2$S in Hepatic Injury**

3.1. **H$_2$S in Hepatic Fibrosis.** Hepatic fibrosis results from chronic damage to the liver in conjunction with the excessive accumulation of the extracellular matrix (ECM) of predominantly type I collagen [82]. A variety of factors such as viral infections, alcohol abuse, genetic abnormalities, overload of metal ions, and autoimmunity contribute to hepatic fibrosis [82, 83]. Hepatic fibrosis is the inevitable pathological process of many chronic liver diseases, including NASH, NAFLD, and viral hepatitis [84]. Once these chronic diseases aggravate further, hepatic fibrosis may progress to liver cirrhosis or hepatocellular carcinoma (HCC) [85]. There is increasing evidence that activated hepatic stellate cells (HSCs) are the central effector cells, which play key roles in the excessive synthesis and deposition of ECM in hepatic interstitium, leading to hepatic fibrosis [82]. Despite the development made in this field, there are limited available treatments for this disease [86, 87]. It is urgent to develop novel therapeutic drugs aimed at attenuating or preventing hepatic fibrosis. It has been reported that CBS deficiency promotes fibrosis, oxidative stress, and steatosis in mice liver, suggesting that H$_2$S is involved in hepatic fibrosis [29]. Furthermore, recent studies have shown that H$_2$S could attenuate hepatic fibrosis both in vivo and in vitro (Table 1). Therefore, H$_2$S may be a promising therapeutic target for the treatment of a variety of fibrotic diseases. The expression levels and roles of H$_2$S-generating enzymes in fibrotic diseases need to be further determined. Furthermore, proper H$_2$S-releasing agents can be designed and developed to treat fibrotic diseases in a controlled way.

3.2. **H$_2$S in Liver Cirrhosis.** Liver cirrhosis is an increasing cause of morbidity and mortality, particularly in developed countries [92]. Liver cirrhosis is a serious condition in which scar tissue replaces the healthy tissue of the liver and regenerative nodules surrounded by fibrous bands in response to the injury [93]. Cirrhosis is the common end of progressive liver disease of various causes, leading to several chronic liver failure entailing complications including peritonitis, hepatic encephalopathy, spontaneous bacterial ascites, and esophageal varices [94]. The major clinical consequences of cirrhosis are impaired liver function, an increased intrahepatic resistance, and the development of HCC [93, 95]. In spite of current advancements in the treatment, orthotopic liver transplantation remains the only definite solution to end-stage cirrhosis [92, 94, 96]. Several studies have demonstrated that the mRNA and protein levels of hepatic CSE and the serum levels of H$_2$S in rats are decreased in the cirrhosis group compared with those in the control group [18, 97, 98]. A hypothesis suggests that H$_2$S may contribute to the pathogenesis of vascular dysfunction in cirrhosis [99]. In addition, treatment with NaHS could attenuate CCl$_4$-induced liver cirrhosis, hepatotoxicity, and portal hypertension through anti-inflammation, antifibrosis, and antioxidation effects in rats, suggesting that targeting H$_2$S may present a promising approach in alleviating liver cirrhosis and portal hypertension [31]. However, more studies are urgently needed to clarify the role and mechanism of H$_2$S in different animal models of liver hepatitis.

3.3. **H$_2$S in Liver Cancer.** Malignant liver tumors can be classified as primary or secondary (metastatic) [100]. Primary malignancies of the liver are HCC, which is the sixth most common cancer and the third leading cause of cancer-related death worldwide [101, 102]. The main etiologic factors for HCC are chronic hepatitis B virus and hepatitis C virus infection, NAFLD, and alcoholic cirrhosis [103]. Most patients with HCC are diagnosed at a late stage when curative treatments are not applicable, and the majority of death is due to tumor recurrence [104]. Thus, it is urgent to uncover novel etiological mechanisms and develop more effective approaches for the prevention and treatment of HCC [105]. In the liver, biosynthesis and clearance of H$_2$S mainly occur in hepatic stellate cells, the major cell source of the extracellular matrix in liver fibrosis and HCC [106]. It has been shown that CSE is overexpressed in human hepatocellular carcinoma HepG2 and PLC/PRF/5 cells and contributes to the proliferation of human HCC cells [107]. Similarly, another study indicates that CSE/H$_2$S promotes human HCC.

| Experimental models         | Effects                                         | Proposed mechanisms                              | Refs. |
|-----------------------------|-------------------------------------------------|-------------------------------------------------|-------|
| Hepatic fibrosis *in vivo* (rat) | NaHS (56 μmol/kg/day) attenuates CCl$_4$-induced hepatic fibrosis | Reduction of liver expression levels of AGTR1 | [20]  |
| Hepatic fibrosis *in vivo* (rat) | NaHS solution (10 mmol/kg body weight) shows protective effects on CCl$_4$-induced hepatic fibrosis | Decreased expression of p38 and increased expression of phospho-Akt | [88]  |
| Hepatic fibrosis *in vivo* (rat) | NaHS solution (10 mmol/kg body weight) attenuates CCl$_4$-induced hepatic fibrosis and ECM expression | Induction of cell cycle arrest and apoptosis in activated hepatic stellate cells | [89]  |
| Hepatic fibrosis *in vivo* (rat) | NaHS (56 μmol/kg/day) attenuates CCl$_4$-induced hepatic fibrosis | Reduction of the expression of TGF-β1 and sediment of ECM in the liver tissues | [90]  |
| Hepatic fibrosis *in vitro* (rat) | DATS (an H$_2$S donor, 10 μM) reduces H$_2$O$_2$-induced upexpression of fibrotic protein in HSCs | Unknown | [91]  |

CCl$_4$: carbon tetrachloride; AGTR1: angiotensin II type 1 receptor; TGF-β1: transforming growth factor-β1; H$_2$O$_2$: hydrogen peroxide.
cell proliferation via cell cycle progression regulation [19]. Furthermore, CBS is overexpressed in human hepatocellular carcinoma HepG2 and SMMC-7721 cells and inhibition of endogenous CBS/H2S could reduce the viability and proliferation of SMMC-7721 cells [108]. Moreover, administration of 500 μmol/L NaHS could induce cell proliferation, migration, and angiogenesis and exhibit antiapoptotic effects in PLC/PRF/5 hepatoma cells via activation of the nuclear factor-κB (NF-κB) pathway [109]. However, treatment with 10⁻³ M NaHS inhibits HCC cell migration, proliferation, and division through induction of cell apoptosis [106]. P-(4-methoxyphenyl)-p-4-morpholinylphosphinothiic acid morpholine salt (GYY4137)-mediated suppression of cell proliferation in human HCC cells may be due to direct targeting of the signal transducer and activator of the transcription 3 pathway [110]. A recent study has demonstrated that the growth and migration of human HCC cells are enhanced by 10-100 μmol/L NaHS and dose-dependently inhibited by 600-1000 μmol/L NaHS through epidermal growth factor receptor/extracellular signal-regulated protein kinase/matrix metalloproteinase 2 and phosphatase and tensin homolog deleted on chromosome ten/protein kinase B (PKB/AKT) signaling pathways [111]. Taken together, these results indicate that endogenous H₂S or relatively low levels of exogenous H₂S may promote the growth of HCC cells, while treatment with higher concentrations of exogenous H₂S may exhibit anticancer effects. Therefore, knockdown/knockout of H₂S-generating enzymes in cancer cells and development of H₂S-releasing donors/drugs may be promising strategies for anticancer therapy.

3.4. H₂S in Hepatic I/R Injury. Hepatic I/R injury is a major complication in many clinical scenarios, such as liver transplantation, trauma, hemorrhagic shock and resuscitation, liver resection, and aortic injury during abdominal surgery [112–114]. Hepatic I/R injury leads to acute or chronic liver failure and increases the rate of morbidity and mortality [115]. Under different pathological conditions, hepatic I/R injury can be classified into warm and cold I/R injury according to the environmental temperature [115]. It is well known that hepatic I/R injury involves several mechanisms, including pH imbalance, calcium overload, mitochondrial dysfunction, ROS overproduction, anaerobic metabolism, activation of Kupffer cells and neutrophils, and the production of cytokines and chemokines [113, 114, 116, 117]. Despite significant improvements in surgical techniques and perioperative care, therapies to suppress hepatic I/R injury at the bedside remain limited largely due to the complex mechanisms [118]. Therefore, there is a clear need for the development of novel agents to protect the liver from I/R injury. An increasing number of studies suggest that H₂S could attenuate hepatic I/R injury in several ways, such as antioxidation, anti-inflammation, antiapoptosis, and AKT activation (Table 2). These results indicate that H₂S plays an important role in attenuating hepatic I/R injury, and targeting H₂S may present a promising approach against I/R-induced liver injury. However, it should be noted that elevated endogenous H₂S could not alleviate hepatic I/R injury in insulin-resistant rats, whereas silymarin preconditioning is able to prevent oxidative, inflammatory, nitrosative, and apoptotic injuries associated with hepatic I/R, which can be attributed to the suppression of endogenous H₂S production [129]. Furthermore, a recent study suggests that brief and repeated ischemic postconditioning (iPoC) could increase the expression of CSE after I/R in diabetes mellitus, and the modulation of CSE may contribute to the renoprotective effect of iPoC [130]. Whether the expression levels of H₂S-generating enzymes in hepatic I/R injury are increased need to be further investigated.

3.5. H₂S in NAFLD/NASH. NAFLD affects approximately 25% of the general adult population and is currently the most common cause of chronic liver disease worldwide [131, 132]. NAFLD is defined as the presence of >5% steatosis, no significant alcohol consumption, and no competing etiologies for hepatic steatosis [133]. Development of NAFLD is associated with metabolic syndrome, such as diabetes, obesity, and dyslipidemia [134]. NASH is considered the progressive form of NAFLD and is characterized by inflammation, hepatocellular injury, liver steatosis, and different degrees of fibrosis [135]. Despite intensive investigations, there are currently no approved therapies for NAFLD/NASH. Therefore, there is an unmet need for developing novel and effective treatments for NAFLD/NASH. Methionine is the most toxic amino acid in mammals. It has been reported that excessive methionine intake induces acute lethal hepatitis in mice lacking CSE [136]. Another study indicates that free fatty acids upregulate hepatic expression of 3-MST and subsequently inhibit the CSE/H₂S pathway, leading to NAFLD [137]. In addition, exercise training can restore bioavailability of H₂S and promote autophagy influx in livers of mice fed with HFD. Recently, a growing number of studies have shown that H₂S could play important roles in NAFLD/NASH (Table 3). Novel H₂S donors and H₂S-releasing drugs can be designed and applied for the treatment of NAFLD/NASH.

3.6. H₂S in Hepatotoxicity. Hepatotoxicity refers to liver injury induced by different types of prescription or nonprescription drugs, such as biological agents, natural medicines, health products, dietary supplements, traditional Chinese medicines (TCMs), and small chemical molecules [140]. TCMs are abundant sources of biologically active substances which have been widely used in the prevention and treatment of human diseases [141–143]. However, an increasing number of studies have shown that TCMs could induce severe adverse effects, such as hepatotoxicity [143–145]. Hepatotoxicity is the leading cause of acute liver failure in the clinic and the main reason that drugs are taken off the market [146]. The wide range of culprit agents and lack of objective diagnostic tests lead to many challenges in the diagnosis and management of hepatotoxicity [147]. In spite of its low incidence in the general population, the possibility of hepatotoxicity in patients with unexplained acute/chronic liver injury needs to be considered [147, 148]. A recent study demonstrates that uranium (U) intoxication decreases endogenous H₂S generation in the hepatic homogenates, while administration of NaHS can reduce U-induced acute hepatotoxicity through antioxidant and antiapoptotic signaling pathways.
in rats [32]. Acetaminophen overdose is one of the leading causes of drug-induced acute liver failure [149]. H₂S treatment alleviates acetaminophen hepatotoxicity in mice partly through antioxidative and anti-inflammatory effects [150]. Another study indicates that H₂S anions could protect against acetaminophen-induced hepatotoxicity by directly scavenging reactive N-acetyl-p-benzoquinone imine [151]. Thus, H₂S has a potential therapeutic value for the treatment of hepatotoxicity.

3.7. H₂S in Acute Liver Failure (ALF). ALF is a rare multiorgan-failure disease that is usually caused by viral hepatitis, ingestion of drugs or toxic substances, or hepatic I/R injury [152]. ALF could lead to rapid deterioration of liver function with subsequent coagulopathy and encephalopathy [153]. ALF patients often require and undergo orthotopic liver transplantation or die due to shortage of donor livers [152]. The major problem in the treatment of ALF is the lack of suitable mechanistic biomarkers and broad-spectrum anti-ALF agents [154]. It has been reported that inhibition of CSE or administration of sodium thiosulfate protects against ALF by increasing thiosulfate levels and upregulating antioxidant and antiapoptotic defense in the liver [27]. Similarly, CSE deficiency protects against the development of multiorgan failure and attenuates the inflammatory response in a murine model of burn [155]. These results suggest that CSE may be a potential therapeutic target in ALF. Whether CBS or 3-MST deficiency can exert similar effects needs to be further investigated.

3.8. Natural Sulfur-Containing Agents in Hepatic Injury. An increasing number of studies have shown that the garlic

### Table 2: Protective effects of H₂S on hepatic I/R injury.

| Experimental models | Effects | Proposed mechanisms | Refs. |
|---------------------|---------|---------------------|-------|
| Hepatic I/R in vivo (rat) | NaHS (14 μM/kg, 30 min prior to I) attenuates the severity of liver injury and inhibits the production of lipid peroxidation, serum inflammatory factors, and apoptosis-related proteins | Antioxidant and antiapoptotic activities | [21] |
| Hepatic I/R in vivo (mouse) | H₂S (100 ppm, 5 min prior to R) protects the liver against I/R injury | Reduction of apoptosis, necrosis, and inflammation | [119] |
| Hepatic I/R in vivo (rat) | GYY4137 (an H₂S donor, 133 μM/kg, 1 h prior to I) attenuates the reduced cell viability and the increased apoptosis induced by hepatic I/R | Activation of the Akt pathway regulated by miR-21 | [120] |
| Hepatic I/R in vivo (rat) | NaHS (12.5, 25, and 50 μM/kg, 5 min prior to I) reduces liver damage after perioperative I/R injury | Inhibition of MPTP opening and the activation of Akt-GSK-3β signaling | [121] |
| Hepatic I/R in vivo (rat) | NaHS (20 μM/kg, 30 min prior to I) reduces hepatic I/R injury in the young rats | Activation of the Nrf2 signaling pathway | [122] |
| Hepatic I/R in vivo (rat) | NaHS (5 mg/kg/d for 11 days) protects against cognitive impairment in rats undergoing hepatic I/R | Reduction of neuroinflammation in the hippocampus | [123] |
| Hepatic I/R in vivo (mouse) | NaHS (1 mg/kg prior to R) ameliorates hepatic I/R injury by direct and indirect antioxidant activities and by accelerating hepatic regeneration | Via mechanisms involving Nrf2 and Akt-p70S6k | [124] |
| Hepatic I/R in vivo (rat) | NaHS (5 mg/kg/d for 11 days) exerts a protective effect on hepatic I/R-induced cognitive impairment | May be associated with the NR2B subunit of the NMDA receptors | [125] |
| Hepatic I/R in vivo (mouse) | NaHS (1.5 mg/kg, 1 h prior to I) protects against hepatic I/R injury | Partly through AKT1 activation | [126] |
| Hepatic I/R in vivo (mouse) | NaHS (14 and 28 μM/kg, 30 min prior to I) attenuates hepatic I/R injury | Partly through regulation of apoptosis via inhibiting JNK1 signaling | [127] |
| Hepatic I/R in vivo (rat) | NaHS (28 μM/kg, prior to R) attenuates hepatic I/R-induced renal and cardiac injury | Reduction of myocardial and renal inflammation and oxidative potential | [128] |
| Hepatic I/R in vivo (mouse) | Na₂S (an H₂S donor, 1 mg/kg, 5 min prior to R) protects the murine liver against I/R injury | Upregulation of intracellular antioxidant and antiapoptotic signaling pathways | [30] |

MPTP: mitochondrial permeability transition pore; GSK-3β: glycogen synthase kinase-3 beta; Nrf2: nuclear factor erythroid 2-related factor 2; NMDA: NR2B subunit of N-methyl-D-aspartate; JNK1: c-Jun N-terminal kinase 1.
constituents possess various biological activities, including antitumorogenic, antioxidative, antimicrobial, antihypertensive, antithrombogenic, hypolipidemic, radioprotective, antitumorogenic, antioxidative, antimicrobial, and anti-inflammatory effects [75, 156–158]. As can be seen in Table 4, many natural sulfur-containing agents can protect against hepatotoxicity mainly through antioxidative, anti-inflammatory, and anti-apoptotic effects. Recent studies have shown that DATS possesses a hepatoprotective effect against carbon tetrachloride-(CCL₄)-induced liver injury and ethanol-induced hepatic steatosis in rats [166–169]. DADS can activate the HO-1/Nrf2 pathway, which may contribute to the protective effects of DADS against ethanol-induced liver injury [170]. Another study demonstrates that DADS increases the levels of phase II/antioxidant enzymes and decreases the levels of inflammatory mediators in CCL₄-induced liver injury [158]. Protective effects of DAS were also observed in lipopolysaccharide/D-galactosamine/mercuric chloride-induced hepatic injury in rats [171, 172]. Furthermore, a recent study reveals that DATS can inhibit the profibrogenic properties and alleviate oxidative stress in hepatic stellate cells through the production of H₂S [91]. Moreover, an increasing number of studies have indicated that DATS, DADS, and DAS could inhibit the growth of human liver cancer cells [173–178]. More efforts should be made to determine the mechanisms of action of natural sulfur-containing agents on liver diseases, such as liver cirrhosis, hepatitis I/R injury, and NAFLD/NASH.

4. Conclusions

The liver plays a key role in glucose and lipid metabolism, antioxidative defense, and xenobiotic metabolism. The liver is one of the major organs for the production and metabolism of H₂S. CSE, CBS, and 3-MST are three main H₂S-generating enzymes, and they contribute to the production of H₂S to

### Table 3: Protective effects of H₂S on NAFLD/NASH.

| Experimental models | Effects | Proposed mechanisms | Refs. |
|---------------------|---------|---------------------|-------|
| NAFLD in vivo (mouse) | NaHS (56 μmol/kg/day) attenuates HFD-induced NAFLD | Activation of liver autophagy via the AMPK-mTOR pathway | [138] |
| NAFLD in vivo (mouse) | NaHS (50 μmol/kg/day) mitigates HFD-induced NAFLD | Improvement of lipid metabolism and antioxidant potential | [49] |
| NAFLD in vivo (mouse) | NaHS (14 μmol/kg) attenuates concanavalin A-induced hepatitis | Inhibition of apoptosis and autophagy partly through activation of the PI3K-AKT1 signaling pathway | [139] |
| NASH in vivo (rat) | NaHS (28 μmol/kg/day) attenuates MCD-induced NASH | Possibly through abating oxidative stress and suppressing inflammation | [22] |
| NAFLD in vivo (mouse) | SPRC (an H₂S donor, 40 mg/kg/day) exerts a novel protective effect on MCD-induced NAFLD | Antioxidative effect through the PI3K/Akt/Nrf2/HO-1 signaling pathway | [50] |

AMPK: adenosine monophosphate-activated protein kinase; mTOR: mammalian target of rapamycin; PI3K: phosphatidylinositol 3-kinase; MCD: methionine-choline-deficient; HO-1: heme oxygenase-1.

### Table 4: Protective effects of natural sulfur-containing agents on hepatotoxicity.

| Experimental models | Effects | Proposed mechanisms | Refs. |
|---------------------|---------|---------------------|-------|
| Hepatotoxicity in vivo (rat) | DATS (40 and 80 mg/kg, orally) protects against valproate-induced hepatotoxicity | Antioxidative, anti-inflammatory, and antiapoptotic properties | [159] |
| Hepatotoxicity in vivo (rat) | DADS (10 ml/kg/day) attenuates acetaminophen-induced acute hepatotoxicity | Possibly via the reduction of oxidative stress-mediated JNK activation and the suppression of inflammatory responses | [160] |
| Hepatotoxicity in vivo (mouse) | AMDS (50 mg/kg/day) protects against acetaminophen-induced hepatotoxicity | Through the strong attenuation of the CD45 expression and HNE formation | [161] |
| Hepatotoxicity in vivo (rat) | DATS (80 mg/kg/day) ameliorates arsenic-induced hepatotoxicity | Abrogation of oxidative stress, inflammation, and apoptosis | [162] |
| Hepatotoxicity in vivo (rat) | DADS (2 ml/kg/day) protects against carbon tetrachloride-induced hepatotoxicity | Through activation of Nrf2 | [163] |
| Hepatotoxicity in vivo (rat) | DAS (200 mg/kg/day) ameliorates ferric nitrolotriacetate-induced hepatotoxicity | Unknown | [164] |
| Hepatotoxicity in vivo (mouse) | DATS (40 mg/kg) protects against isoniazid and rifampicin-induced hepatotoxicity | Reduction of oxidative stress and activation of Kupffer cells | [165] |

AMDS: allyl methyl disulphide; HNE: human neutrophil elastase.
different extents in the liver. Whether the liver could produce H₂S via another enzyme/pathway needs to be further investigated and confirmed. H₂S is the third gaseous signaling molecule that is involved in glucose and lipid metabolism, cell differentiation, and circadian rhythm in the liver. Further studies are needed to determine the effects of endogenous H₂S on hepatic physiological processes. It is worth noting that H₂S could exhibit two obviously opposite effects on hepatic vasculature, oxidative stress, and mitochondrial function, which can be attributed to the concentration, time frame, and reaction time of H₂S, as well as the differences between disease stages or models. In light of the important roles of nitric oxide (NO) and carbon monoxide (CO) in mammalian biology, whether H₂S exerts the regulatory effects by interacting with NO and/or CO should be clarified.

Recent studies indicate that treatment with exogenous H₂S could protect against a number of liver diseases, including hepatic fibrosis, liver cirrhosis, NAFLD/NASH, and hepatotoxicity. Novel H₂S releasing/stimulating reagents can be designed and applied to enhance the therapeutic effects. An increasing number of evidence suggests that endogenous H₂S or relatively low levels of exogenous H₂S can promote the growth of HCC cells, while treatment with higher concentrations of H₂S for a relatively long period

![Figure 2: A proposed mechanism of the effect of H₂S on the growth and death of cancer. (a) A normal distribution curve is employed to explain the effect of H₂S on the development of cancer. Endogenous H₂S or relatively low levels of exogenous H₂S could promote cancer cell growth, while knockdown/knockout of the expression of H₂S-generating enzyme or exposure of relatively high concentrations of H₂S could induce cancer cell death. (b, A1) Downregulation of endogenous H₂S induces cancer cell death. (c, A2) A certain concentration of H₂S induces growth arrest in cancer cells. (d, A3) Normal level of H₂S in cancer cells promotes cancer cell growth. (e, A4) Treatment with relatively low levels of exogenous H₂S could exert optimal effects on the growth of cancer cells. (f-h, A5-A7) Along with the increase in the levels of exogenous H₂S, the growth of cancer cells is gradually decreased. It is worth noting that the procession of cancer cells is theoretically the same between A1 and A7, A2 and A6, and A3 and A5.](image)
may exhibit balance between the pro- and anticancer effects induced by H₂S (Figure 2). Therefore, inhibition of the generation of endogenous H₂S or administration of relatively high level of exogenous H₂S could be effective in suppressing tumor growth. In addition, H₂S could attenuate hepatic I/R injury in several ways, such as antioxidation, anti-inflammation, antiapoptosis, and AKT activation. Nevertheless, another study has shown that the increases in endogenous H₂S exacerbate hepatic I/R injury, suggesting that increased levels of H₂S may exhibit opposite effects. Furthermore, inhibition of CSE could alleviate ALF through upregulation of antioxidant and antiapoptotic defense in the liver. Novel inhibitors that target H₂S-generating enzymes could be designed and applied in the treatment of ALF.

In conclusion, with a deeper understanding of the precise mechanisms behind the roles of H₂S in liver health and disease, H₂S could be a promising therapeutic target for further preclinical and clinical research.

Conflicts of Interest

The authors declare that they have no conflicts of interest related to this work.

Acknowledgments

This work was supported by grants from the National Natural Science Foundation of China (Nos. U1504817, 81670088), the Foundation of Science & Technology Department of Henan Province, China (Nos. 182102310335, 172102410019), the Natural Science Foundation of Education Department of Henan Province, China (No. 15A310017), the Science Foundation of Kaifeng City, China (Nos. 1608004, 1703016), and the Science Foundation of Henan University, China (No. yqpy20170044).

References

[1] T. V. Mishanina, M. Libiad, and R. Banerjee, “Biogenesis of reactive sulfur species for signaling by hydrogen sulfide oxidation pathways,” Nature Chemical Biology, vol. 11, no. 7, pp. 457–464, 2015.

[2] J. L. Wallace and R. Wang, “Hydrogen sulfide-based therapeutics: exploiting a unique but ubiquitous gasotransmitter,” Nature Reviews Drug Discovery, vol. 14, no. 5, pp. 329–345, 2015.

[3] R. Wang, “Physiological implications of hydrogen sulfide: a whiff exploration that blossomed,” Physiological Reviews, vol. 92, no. 2, pp. 791–896, 2012.

[4] C. Alvarez, I. Garcia, I. Moreno et al., “Cysteine-generated sulfide in the cytosol negatively regulates autophagy and modulates the transcriptional profile in Arabidopsis,” The Plant Cell, vol. 24, no. 11, pp. 4621–4634, 2012.

[5] B. D. Paul and S. H. Snyder, “H₂S signalling through protein sulphydration and beyond,” Nature Reviews Molecular Cell Biology, vol. 13, no. 8, pp. 499–507, 2012.

[6] C. Szabo, C. Coletta, C. Chao et al., “Tumor-derived hydrogen sulfide, produced by cystathionine-β-synthase, stimulates bioenergetics, cell proliferation, and angiogenesis in colon cancer,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 30, pp. 12474–12479, 2013.

[7] D. Wu, H. Wang, T. Teng, S. Duan, A. Ji, and Y. Li, “Hydrogen sulfide and autophagy: a double edged sword,” Pharmacological Research, vol. 131, pp. 120–127, 2018.

[8] N. Shibuya, S. Koike, M. Tanaka et al., “A novel pathway for the production of hydrogen sulfide from D-cysteine in mammalian cells,” Nature Communications, vol. 4, no. 1, p. 1366, 2013.

[9] A. Papapetropoulos, A. Pyriochou, Z. Altaany et al., “Hydrogen sulfide is an endogenous stimulator of angiogenesis,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 51, pp. 21972–21977, 2009.

[10] G. Yang, L. Wu, B. Jiang et al., “H₂S as a physiologic vasorelaxant: hypertension in mice with deletion of cystathionine γ-lyase,” Science, vol. 322, no. 5901, pp. 587–590, 2008.

[11] D. K. Ma, R. Vozdek, N. Bhatla, and H. R. Horvitz, “CYSL-1 interacts with the O₂-sensing hydroxylase EGL-9 to promote H₂S-modulated hypoxia-induced behavioral plasticity in C. elegans,” Neuron, vol. 73, no. 5, pp. 925–940, 2012.

[12] S. Mani, W. Cao, L. Wu, and R. Wang, “Hydrogen sulfide and the liver,” Nitric Oxide, vol. 41, pp. 62–71, 2014.

[13] B. Gao, W. I. Jeong, and Z. Tian, “Liver: an organ with predominant innate immunity,” Hepatology, vol. 47, no. 2, pp. 729–736, 2008.

[14] S. Liu, J. D. Brown, K. J. Stanya et al., “A diurnal serum lipid integrates hepatic lipogenesis and peripheral fatty acid use,” Nature, vol. 502, no. 7472, pp. 550–554, 2013.

[15] E. J. Norris, C. R. Culberston, S. Narasimhan, and M. G. Clemens, “The liver as a central regulator of hydrogen sulfide,” Shock, vol. 36, no. 3, pp. 242–250, 2011.

[16] Y. Ju, A. Untereiner, L. Wu, and G. Yang, “H₂S-induced 3-sulphydration of pyruvate carboxylase contributes to gluconeogenesis in liver cells,” Biochimica et Biophysica Acta (BBA) General Subjects, vol. 1850, no. 11, pp. 2293–2303, 2015.

[17] J. Pichette and J. Gagnon, “Implications of hydrogen sulfide in glucose regulation: how H₂S can alter glucose homeostasis through metabolic hormones,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 3285074, 5 pages, 2016.

[18] S. Fiorucci, E. Antonelli, A. Mencarelli et al., “The third gas: H₂S regulates perfusion pressure in both the isolated and perfused normal rat liver and in cirrhosis,” Hepatology, vol. 42, no. 3, pp. 539–548, 2005.

[19] P. Yin, C. Zhao, Z. Li et al., “Sp1 is involved in regulation of cystathionine γ-lyase gene expression and biological function by PI3K/Akt pathway in human hepatocellular carcinoma cell lines,” Cellular Signalling, vol. 24, no. 6, pp. 1229–1240, 2012.

[20] H.-N. Fan, N. W. Chen, W. L. Shen, X. Y. Zhao, and J. Zhang, “Endogenous hydrogen sulfide is associated with angiogenesis II type 1 receptor in a rat model of carbon tetrachloride-induced hepatic fibrosis,” Molecular Medicine Reports, vol. 12, no. 3, pp. 3351–3358, 2015.

[21] K. Kang, M. Zhao, H. Jiang, G. Tan, S. Pan, and X. Sun, “Role of hydrogen sulfide in hepatic ischemia-reperfusion-induced injury in rats,” Liver Transplantation, vol. 15, no. 10, pp. 1306–1314, 2009.

[22] Z. L. Luo, L. J. Tang, T. Wang et al., “Effects of treatment with hydrogen sulfide on methionine-choline deficient diet-induced non-alcoholic steatohepatitis in rats,” Journal
Oxidative Medicine and Cellular Longevity

of Gastroenterology and Hepatology, vol. 29, no. 1, pp. 215–222, 2014.

[23] S. Di Meo, T. T. Reed, P. Venditti, and V. M. Victor, “Role of ROS and RNS sources in physiological and pathological conditions,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 1245049, 44 pages, 2016.

[24] S. J. Forrester, D. S. Kikuchi, M. S. Hernandes, Q. Xu, and K. K. Griendling, “Reactive oxygen species in metabolic and inflammatory signaling,” Circulation Research, vol. 122, no. 6, pp. 877–902, 2018.

[25] M. Schieber and N. S. Chandel, “ROS function in redox signaling and oxidative stress,” Current Biology, vol. 24, no. 10, pp. R453–R462, 2014.

[26] D. Bartolini, K. Dallaglio, P. Torquato, M. Piroddi, and F. Galli, “Nrf2-p62 autopagy pathway and its response to oxidative stress in hepatocellular carcinoma,” Translational Research, vol. 193, pp. 54–71, 2016.

[27] K. Shirozu, K. Tokuda, E. Marutani, D. Lefer, R. Wang, and F. Ichinose, “Cystathionine γ-lyase deficiency protects mice from galactosamine/lipopolysaccharide-induced acute liver failure,” Antioxidants & Redox Signaling, vol. 20, no. 2, pp. 204–216, 2014.

[28] Y. Guo, B. Hu, H. Huang et al., “Estrogen sulfotransferase is an oxidative stress-responsive gene that gender-specifically affects liver ischemia/reperfusion injury,” The Journal of Biological Chemistry, vol. 290, no. 23, pp. 14754–14764, 2015.

[29] K. Robert, J. Nehmé, E. Bourdon et al., “Cystathionine beta synthase deficiency promotes oxidative stress, fibrosis, and steatosis in mice liver,” Gastroenterology, vol. 128, no. 5, pp. 1405–1415, 2005.

[30] S. Jha, J. W. Calvert, M. R. Duranski, A. Ramachandran, and D. J. Lefer, “Hydrogen sulfide attenuates hepatic ischemia-reperfusion injury: role of antioxidant and antiapoptotic signaling,” American Journal of Physiology-Heart and Circulatory Physiology, vol. 295, no. 2, pp. H801–H806, 2008.

[31] G. Tan, S. Pan, J. Li et al., “Hydrogen sulfide attenuates carbon tetrachloride-induced hepatotoxicity, liver cirrhosis and portal hypertension in rats,” PLoS One, vol. 6, no. 10, article e25943, 2011.

[32] Y. Yuan, J. Zheng, T. Zhao, X. Tang, and N. Hu, “Hydrogen sulfide alleviates uranium-induced acute hepatotoxicity in rats: role of antioxidant and antiapoptotic signaling,” Environmental Toxicology, vol. 32, no. 2, pp. 581–593, 2017.

[33] D. H. Truong, M. A. Eghbal, W. Hindmarsh, S. H. Roth, and P. J. O’Brien, “Molecular mechanisms of hydrogen sulfide toxicity,” Drug Metabolism Reviews, vol. 38, no. 4, pp. 733–744, 2006.

[34] A. von Wilamowitz-Moellendorff, R. W. Hunter, M. García-Rocha et al., “Glucose-6-phosphate-mediated activation of liver glycogen synthase plays a key role in hepatic glycogen synthesis,” Diabetes, vol. 62, no. 12, pp. 4070–4082, 2013.

[35] M. C. Petersen, D. F. Vatner, and G. I. Shulman, “Regulation of hepatic glucose metabolism in health and disease,” Nature Reviews Endocrinology, vol. 13, no. 10, pp. 572–587, 2017.

[36] A. K. Rines, K. Sharabi, C. D. J. Tavares, and P. Puigserver, “Targeting hepatic glucose metabolism in the treatment of type 2 diabetes,” Nature Reviews Drug Discovery, vol. 15, no. 11, pp. 786–804, 2016.

[37] B. S. Hijmans, A. Boss, T. H. van Dijk et al., “Hepatocytes contribute to residual glucose production in a mouse model for glycogen storage disease type 1a,” Hepatology, vol. 66, no. 6, pp. 2042–2054, 2017.

[38] P. Manna, N. Gongor, R. McVie, and S. K. Jain, “Decreased cystathionine-γ-lyase (CSE) activity in livers of type 1 diabetic rats and peripheral blood mononuclear cells (PBMC) of type 1 diabetic patients,” The Journal of Biological Chemistry, vol. 289, no. 17, pp. 11767–11778, 2014.

[39] J. Beltowska, G. Wójcicka, and A. Jamroz-Wiśniewska, “Hydrogen sulfide in the regulation of insulin secretion and insulin sensitivity: implications for the pathogenesis and treatment of diabetes mellitus,” Biochemical Pharmacology, vol. 149, pp. 60–76, 2018.

[40] A. A. Untereiner, R. Wang, Y. Lu, and L. Wu, “Decreased gluconeogenesis in the absence of cystathionine gamma-lyase and the underlying mechanisms,” Antioxidants & Redox Signaling, vol. 24, no. 3, pp. 129–140, 2016.

[41] L. Zhang, G. Yang, A. Untereiner, Y. Ju, L. Wu, and R. Wang, “Hydrogen sulfide impairs glucose utilization and increases gluconeogenesis in hepatocytes,” Endocrinology, vol. 154, no. 1, pp. 114–126, 2013.

[42] H. Zhou and R. Liu, “ER stress and hepatic lipid metabolism,” Frontiers in Genetics, vol. 5, p. 112, 2014.

[43] L. P. Bechmann, R. A. Hannivoor, G. Gerken, G. S. Hotamisligil, M. Trauner, and A. Canbay, “The interaction of hepatic lipid and glucose metabolism in liver diseases,” Journal of Hepatology, vol. 56, no. 4, pp. 952–964, 2012.

[44] D. B. Jump, “Fatty acid regulation of hepatic lipid metabolism,” Current Opinion in Clinical Nutrition and Metabolic Care, vol. 14, no. 2, pp. 115–120, 2011.

[45] J. Hamelet, K. Demuth, J. L. Paul, J. M. Delabar, and N. Janel, “Hyperhomocysteinemia due to cystathionine beta synthase deficiency induces dysregulation of genes involved in hepatic lipid homeostasis in mice,” Journal of Hepatology, vol. 46, no. 1, pp. 151–159, 2007.

[46] K. Namekata, Y. Enokido, I. Ishii, Y. Nagai, T. Harada, and H. Kimura, “Abnormal lipid metabolism in cystathionine beta-synthase-deficient mice, an animal model for hyperhomocysteinemia,” The Journal of Biological Chemistry, vol. 279, no. 51, pp. 52961–52969, 2004.

[47] S. Y. Hwang, L. K. Sarna, Y. L. Siow, and K. O, “High-fat diet stimulates hepatic cystathionine β-synthase and cystathionine γ-lyase expression,” Canadian Journal of Physiology and Pharmacology, vol. 91, no. 11, pp. 913–919, 2013.

[48] L. K. Sarna, V. Sid, P. Wang, Y. L. Siow, J. D. House, and K. O, “Tyrosol attenuates high fat diet-induced hepatic oxidative stress: potential involvement of cystathionine β-synthase and cystathionine γ-lyase,” Lipids, vol. 51, no. 5, pp. 583–590, 2016.

[49] D. Wu, N. Zheng, K. Qi et al., “Exogenous hydrogen sulfide mitigates the fatty liver in obese mice through improving lipid metabolism and antioxidant potential,” Medical Gas Research, vol. 5, no. 1, p. 1, 2015.

[50] W. Li, F. Ma, L. Zhang et al., “S-Propargyl-cysteine exerts a novel protective effect on methionine and choline deficient diet-induced fatty liver via Akt/Nrf2/HO-1 pathway,” Oxidative Medicine and Cellular Longevity, vol. 2016, Article ID 4690857, 17 pages, 2016.

[51] K. M. Elsayes, A. M. Shaaban, S. M. Rothan et al., “A comprehensive approach to hepatic vascular disease,” Radiographics, vol. 37, no. 3, pp. 813–836, 2017.
[52] G. Noussios, I. Dimitriou, I. Chatzis, and A. Katsourakis, “The main anatomic variations of the hepatic artery and their importance in surgical practice: review of the literature,” Journal of Clinical Medical Research, vol. 9, no. 4, pp. 248–252, 2017.

[53] K. M. Holwerda, S. A. Karumanchi, and A. T. Lely, “Hydrogen sulfide: role in vascular physiology and pathology,” Current Opinion in Nephrology and Hypertension, vol. 24, no. 2, pp. 170–176, 2015.

[54] E. J. Norris, S. Larion, C. R. Culberson, and M. G. Clemens, “Hydrogen sulfide differentially affects the hepatic vasculature in response to phynylephrine and endothelin 1 during endotoxemia,” Shock, vol. 39, no. 2, pp. 168–175, 2013.

[55] N. Siebert, D. Cantré, C. Eipel, and B. Vollmar, “H2S contributes to the hepatic arterial buffer response and mediates vaso-relaxation of the hepatic artery via activation of K (ATP) channels,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 295, no. 6, pp. G1266–G1273, 2008.

[56] E. J. Norris, N. Feilen, N. H. Nguyen et al., “Hydrogen sulfide modulates sinusoidal constriction and contributes to hepatic microcirculatory dysfunction during endotoxemia,” American Journal of Physiology-Gastrointestinal and Liver Physiology, vol. 304, no. 12, pp. G1070–G1078, 2013.

[57] J. R. Friedman, A. Mourier, J. Yamada, J. M. McCaffery, and J. Nunnari, “MICOS coordinates with respiratory complexes and lipids to establish mitochondrial inner membrane architecture,” eLife, vol. 4, article e07739, 2015.

[58] M. M. Mehta, S. E. Weinberg, and N. S. Chandel, “Mitochondrial control of immunity: beyond ATP,” Nature Reviews Immunology, vol. 17, no. 10, pp. 608–620, 2017.

[59] F. Nassir and J. A. Ibda, “Role of mitochondria in alcoholic liver disease,” World Journal of Gastroenterology, vol. 20, no. 9, pp. 2136–2142, 2014.

[60] H. Teng, B. Wu, K. Zhao, G. Yang, L. Wu, and R. Wang, “Oxygen-sensitive mitochondrial accumulation of cystathionine β-synthase mediated by Lon protease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 110, no. 31, pp. 12679–12684, 2013.

[61] A. A. Untereiner, M. Fu, K. Módis, R. Wang, Y. J. Ju, and L. Wu, “Stimulatory effect of CSS-generated HS on hepatic mitochondrial biogenesis and the underlying mechanisms,” Nitric Oxide, vol. 58, pp. 67–76, 2016.

[62] K. Módis, C. Coletta, K. Erdélyi, A. Papapetropoulos, and C. Szabo, “Intramitochondrial hydrogen sulfide production by 3-mercaptoppyruvate sulfurtransferase maintains mitochondrial electron flow and supports cellular bioenergetics,” The FASEB Journal, vol. 27, no. 2, pp. 601–611, 2013.

[63] C. Hu and L. Li, “In vitro and in vivo hepatic differentiation of adult somatic stem cells and extraembryonic stem cells for treating end stage liver diseases,” Stem Cells International, vol. 2015, Article ID 871972, 11 pages, 2015.

[64] W. H. Liu, F. Q. Song, L. N. Ren et al., “The multiple functional roles of mesenchymal stem cells in participating in treating liver diseases,” Journal of Cellular and Molecular Medicine, vol. 19, no. 3, pp. 511–520, 2015.

[65] R. Vasconcellos, É. C. Alvarenga, R. C. Parreira, S. S. Lima, and R. R. Resende, “Exploring the cell signalling in hepatocyte differentiation,” Cellular Signalling, vol. 28, no. 11, pp. 1773–1788, 2016.

[66] N. Ishkhitiev, B. Calenic, I. Aoyama, H. Ii, K. Yaegaki, and T. Imai, “Hydrogen sulfide increases hepatic differentiation in tooth-pulp stem cells,” Journal of Breath Research, vol. 6, no. 1, article 017103, 2012.

[67] M. Okada, N. Ishkitiev, K. Yaegaki et al., “Hydrogen sulphide increases hepatic differentiation of human tooth pulp stem cells compared with human bone marrow stem cells,” International Endodontic Journal, vol. 47, no. 12, pp. 1142–1150, 2014.

[68] A. L. C. Figueroa, H. Figueiredo, S. A. Rebuffat, E. Vieira, and R. Gomis, “Taurine treatment modulates circadian rhythms in mice fed a high fat diet,” Scientific Reports, vol. 6, no. 1, article 36801, 2016.

[69] Y. Tahara and S. Shibata, “Circadian rhythms of liver physiology and disease: experimental and clinical evidence,” Nature Reviews Gastroenterology & Hepatology, vol. 13, no. 4, pp. 217–226, 2016.

[70] X. Tong and L. Yin, “Circadian rhythms in liver physiology and liver diseases,” Comprehensive Physiology, vol. 3, no. 2, pp. 917–940, 2013.

[71] Z. Shang, C. Lu, S. Chen, L. Hua, and R. Qian, “Effect of H2S on the circadian rhythm of mouse hepatocytes,” Lipids in Health and Disease, vol. 11, no. 1, p. 23, 2012.

[72] J. H. Jeong, H. R. Jeong, Y. N. Jo, H. J. Kim, H. J. Shin, and H. J. Heo, “Ameliorating effects of aged garlic extracts against Aβ-induced neurotoxicity and cognitive impairment,” BMC Complementary and Alternative Medicine, vol. 13, no. 1, p. 268, 2013.

[73] S. Annamalai, L. Mohanam, V. Raja, A. Dev, and V. Prabhu, “Antibesity, antioxidant and hepatoprotective effects of diallyl trisulphide (DATS) alone or in combination with orlistat on HFD induced obese rats,” Biomedicine & Pharmacotherapy, vol. 93, pp. 81–87, 2017.

[74] T. Sueyoshi, W. D. Green, K. Vinal, T. S. Woodrum, R. Moore, and M. Negishi, “Garlic extract diallyl sulfide (DAS) activates nuclear receptor CAR to induce the Sult1e1 gene in mouse liver,” PLoS One, vol. 6, no. 6, article e21229, 2011.

[75] C. Yang, L. Li, L. Yang, H. Lü, S. Wang, and G. Sun, “Anti-obesity and Hypolipidemic effects of garlic oil and onion oil in rats fed a high-fat diet,” Nutrition and Metabolism, vol. 15, no. 1, p. 43, 2018.

[76] H. L. Nicastro, S. A. Ross, and J. A. Milner, “Garlic and onions: their cancer prevention properties,” Cancer Prevention Research, vol. 8, no. 3, pp. 181–189, 2015.

[77] T. Fukao, T. Hosono, S. Misawa, T. Seki, and T. Ariga, “The effects of allyl sulfides on the induction of phase II detoxification enzymes and liver injury by carbon tetrachloride,” Food and Chemical Toxicology, vol. 42, no. 5, pp. 743–749, 2004.

[78] C. C. Wu, L. Y. Sheen, H. W. Chen, S. J. Tsai, and C. K. Lii, “Effects of organosulfur compounds from garlic oil on the antioxidation system in rat liver and red blood cells,” Food and Chemical Toxicology, vol. 39, no. 6, pp. 563–569, 2001.

[79] M. Ciecik, M. Görny, A. Bílska-Willkosz, and D. Kowalczyk-Pachel, “Is aldehyde dehydrogenase inhibited by sulfur compounds? In vitro and in vivo studies,” Acta Biochimica Polonica, vol. 65, no. 1, pp. 125–132, 2018.

[80] D. Wu, Q. Hu, and Y. Zhu, “Therapeutic application of hydrogen sulfide donors: the potential and challenges,” Frontiers in Medicine, vol. 10, no. 1, pp. 18–27, 2016.

[81] D. Liang, H. Wu, M. W. Wong, and D. Huang, “Diallyl trisulphide is a fast H2S donor, but diallyl disulphide is a slow one: the reaction pathways and intermediates of glutathione with...
polysulfides,” *Organic Letters*, vol. 17, no. 17, pp. 4196–4199, 2015.

[82] M. M. Ni, Y. R. Wang, W. W. Wu et al., “Novel insights on notch signaling pathways in liver fibrosis,” *European Journal of Pharmacology*, vol. 826, pp. 66–74, 2018.

[83] S. Poilil Surendran, R. George Thomas, M. J. Moon, and Y. Y. Jeong, “Nanoparticles for the treatment of liver fibrosis,” *International Journal of Nanomedicine*, vol. 12, pp. 6997–7006, 2017.

[84] J. Lambrecht, I. Mannaerts, and L. A. van Grunsven, “The role of miRNAs in stress-responsive hepatic stellate cells during liver fibrosis,” *Frontiers in Physiology*, vol. 6, p. 209, 2015.

[85] X. P. Jiang, W. B. Ai, L. Y. Wan, Y. Q. Zhang, and J. F. Wu, “The roles of microRNA families in hepatic fibrosis,” *Cell & Bioscience*, vol. 7, no. 1, p. 34, 2017.

[86] B. González-Fernández, D. I. Sánchez, J. González-Gallego, and M. J. Tuñón, “Sphingosine 1-phosphate signaling as a target in hepatic fibrosis therapy,” *Frontiers in Pharmacology*, vol. 8, p. 579, 2017.

[87] C. Y. Zhang, W. G. Yuan, P. He, J. H. Lei, and C. X. Wang, “Liver fibrosis and hepatic stellate cells: etiology, pathological hallmarks and therapeutic targets,” *World Journal of Gastroenterology*, vol. 22, no. 48, pp. 10512–10522, 2016.

[88] H. N. Fan, H. J. Wang, L. Ren et al., “Decreased expression of p38 MAPK mediates protective effects of hydrogen sulfide on hepatic fibrosis,” *European Review for Medical and Pharmacological Sciences*, vol. 17, no. 5, pp. 644–652, 2013.

[89] H.-N. Fan, H.-J. Wang, C.-R. Yang-Dan et al., “Protective effects of hydrogen sulfide on oxidative stress and fibrosis in hepatic stellate cells,” *Molecular Medicine Reports*, vol. 7, no. 1, pp. 247–253, 2013.

[90] Q. Shen, Z. Qin, and A. Lu, “Preventive effect of exogenous hydrogen sulfide on hepatic fibrosis in rats,” *Zhong Nan Da Xue Xue Bao Yi Xue Ban*, vol. 37, no. 9, pp. 911–915, 2012.

[91] F. Zhang, H. Jin, L. Wu et al., “Diallyl trisulfide suppresses oxidative stress-induced activation of hepatic stellate cells through production of hydrogen sulfide,” *Oxidative Medicine and Cellular Longevity*, vol. 2017, Article ID 1406726, 13 pages, 2017.

[92] E. A. Tschochatzis, J. Bosch, and A. K. Burroughs, “Liver cirrhosis,” *The Lancet*, vol. 383, no. 9930, pp. 1749–1761, 2014.

[93] D. Schuppan and N. H. Afdhal, “Liver cirrhosis,” *The Lancet*, vol. 371, no. 9615, pp. 838–851, 2008.

[94] K. A. Kwak, H. J. Cho, J. Y. Yang, and Y. S. Park, “Current perspectives regarding stem cell-based therapy for liver cirrhosis,” *Canadian Journal of Gastroenterology and Hepatology*, vol. 2018, Article ID 4197857, 19 pages, 2018.

[95] A. Forner, M. Reig, and J. Bruix, “Hepatocellular carcinoma,” *The Lancet*, vol. 391, no. 10127, pp. 1301–1314, 2018.

[96] R. Lozano, M. Naghavi, K. Foreman et al., “Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010,” *The Lancet*, vol. 380, no. 9859, pp. 2095–2128, 2012.

[97] S.-B. Guo, Z.-J. Duan, Q.-M. Wang, Q. Zhou, Q. Li, and X.-Y. Sun, “Endogenous carbon monoxide downregulates hepatic cystathionine-γ-lyase in rats with liver cirrhosis,” *Experimental and Therapeutic Medicine*, vol. 10, no. 6, pp. 2039–2046, 2015.

[98] W. Wei, C. Wang, and D. Li, “The content of hydrogen sulfide in plasma of cirrhosis rats combined with portal hypertension and the correlation with indexes of liver function and liver fibrosis,” *Experimental and Therapeutic Medicine*, vol. 14, no. 5, pp. 5022–5026, 2017.

[99] M. R. Ebrahimkhani, A. R. Mani, and K. Moore, “Hydrogen sulphide and the hyperdynamic circulation in cirrhosis: a hypothesis,” *Gut*, vol. 54, no. 12, pp. 1668–1671, 2005.

[100] G. Khemlina, S. Ikeda, and R. Kurzrock, “The biology of hepatocellular carcinoma: implications for genomic and immune therapies,” *Molecular Cancer*, vol. 16, no. 1, p. 149, 2017.

[101] A. X. Zhu, D. G. Duda, D. V. Sahani, and R. K. Jain, “HCC and angiogenesis: possible targets and future directions,” *Nature Reviews Clinical Oncology*, vol. 8, no. 5, pp. 292–301, 2011.

[102] X. Shi, H. R. Zhu, T. T. Liu, X. Z. Shen, and J. M. Zhu, “The hippo pathway in hepatocellular carcinoma: non-coding RNAs in action,” *Cancer Letters*, vol. 400, pp. 175–182, 2017.

[103] S. Singh, P. P. Singh, L. R. Roberts, and W. Sanchez, “Chemopreventive strategies in hepatocellular carcinoma,” *Nature Reviews Gastroenterology & Hepatology*, vol. 11, no. 1, pp. 45–54, 2014.

[104] J. H. Shi and P. D. Line, “Effect of liver regeneration on malignant hepatic tumors,” *World Journal of Gastroenterology*, vol. 20, no. 43, pp. 16167–16177, 2014.

[105] G. Xu, J. Wang, F. Wu et al., “YAP and 14–3–3 y are involved in HS-OA-induced growth inhibition of hepatocellular carcinoma cells: a novel mechanism for hydrogen sulfide releasing oleandonic acid,” *Oncotarget*, vol. 7, no. 32, pp. 52150–52165, 2016.

[106] S. S. Wang, Y. H. Chen, N. Chen et al., “Hydrogen sulfide promotes autophagy of hepatocellular carcinoma cells through the PI3K/Akt/mTOR signaling pathway,” *Cell Death & Disease*, vol. 8, no. 3, article e2688, 2017.

[107] Y. Pan, S. Ye, D. Yuan, J. Zhang, Y. Bai, and C. Shao, “Hydrogen sulfide (H2S)/cystathionine-γ-lyase (CSE) pathway contributes to the proliferation of hepatoma cells,” *Mutation Research*, vol. 763–764, pp. 10–18, 2014.

[108] H. Jia, J. Ye, J. You, X. Shi, W. Kang, and T. Wang, “Role of the cystathionine β-synthase/H2S system in liver cancer cells and the inhibitory effect of quinolone-indolone conjugate QC2 on the system,” *Oncology Reports*, vol. 37, no. 5, pp. 3001–3009, 2017.

[109] Y. Zhen, W. Pan, F. Hu et al., “Exogenous hydrogen sulfide exerts proliferation/anti-apoptosis/angiogenesis/migration effects via activating the activation of NF-κB pathway in PLC/PRF/5 hepatoma cells,” *International Journal of Oncology*, vol. 46, no. 5, pp. 2194–2204, 2015.

[110] S. Lu, Y. Gao, X. Huang, and X. Wang, “GYY 4137, a hydrogen sulfide (H2S) donor, shows potent anti-hepatocellular carcinoma activity through blocking the STAT3 pathway,” *International Journal of Oncology*, vol. 44, no. 4, pp. 1259–1267, 2014.

[111] D. Wu, M. Li, W. Tian et al., “Hydrogen sulfide acts as a double-edged sword in human hepatocellular carcinoma cells through EGFR/ERK/MMP-2 and PTEN/AKT signaling pathways,” *Scientific Reports*, vol. 7, no. 1, article 5134, 2017.

[112] C. Nastos, K. Kalimeris, N. Papoutsidakis et al., “Global consequences of liver ischemia/reperfusion injury,” *Oxidative Medicine and Cellular Longevity*, vol. 2014, Article ID 906965, 13 pages, 2014.
[113] Y. Zhai, H. Petrowsky, J. C. Hong, R. W. Busuttil, and J. W. Kupiec-Weglinski, “Ischaemia-reperfusion injury in liver transplantation—from bench to bedside,” Nature Reviews Gastroenterology & Hepatology, vol. 10, no. 2, pp. 79–89, 2013.

[114] D. Wu, J. Wang, H. Li, M. Xue, A. Ji, and Y. Li, “Role of hydrogen sulfide in ischemia-reperfusion injury,” Oxidative Medicine and Cellular Longevity, vol. 2015, Article ID 188908, 16 pages, 2015.

[115] C. Hu and L. Li, “Pre-conditions for eliminating mitochondrial dysfunction and maintaining liver function after hepatic ischaemia reperfusion,” Journal of Cellular and Molecular Medicine, vol. 21, no. 9, pp. 1719–1731, 2017.

[116] Z. Ma, Z. Xin, W. Di et al., “Melatonin and mitochondrial function during ischemia/reperfusion injury,” Cellular and Molecular Life Sciences, vol. 74, no. 21, pp. 3989–3998, 2017.

[117] Y. Q. Zhang, N. Ding, Y. F. Zeng et al., “New progress in roles of nitric oxide during hepatic ischemia reperfusion injury,” World Journal of Gastroenterology, vol. 23, no. 14, pp. 2505–2510, 2017.

[118] K. L. Go, S. Lee, I. Zendejas, K. E. Behrns, and J. S. Kim, “Mitochondrial dysfunction and autophagy in hepatic ischemia/reperfusion injury,” BioMed Research International, vol. 2015, Article ID 183469, 14 pages, 2015.

[119] E. M. Bos, P. M. Snijder, H. Jekel et al., “Beneficial effects of gaseous hydrogen sulfide in hepatic ischemia/reperfusion injury,” Transplant International, vol. 25, no. 8, pp. 897–902, 2012.

[120] M. Lu, X. Jiang, L. Tong et al., “MicroRNA-21-regulated activation of the Akt pathway participates in the protective effects of H2S against liver ischemia-reperfusion injury,” Biological & Pharmaceutical Bulletin, vol. 41, no. 2, pp. 229–238, 2018.

[121] Q. Zhang, H. Fu, H. Zhang et al., “Hydrogen sulfide preconditioning protects rat liver against ischemia/reperfusion injury by activating Akt-GSK-3β signaling and inhibiting mitochondrial permeability transition,” PLoS One, vol. 8, no. 9, article e74422, 2013.

[122] X. Huang, Y. Gao, J. Qin, and S. Lu, “The role of miR-34a in the hepatoprotective effect of hydrogen sulfide on ischemia/reperfusion injury in young and old rats,” PLoS One, vol. 9, no. 11, article e113305, 2014.

[123] F. Tu, J. Li, J. Wang, Q. Li, and W. Chu, “Hydrogen sulfide protects against cognitive impairment induced by hepatic ischemia and reperfusion via attenuating neuroinflammation,” Experimental Biology and Medicine, vol. 241, no. 6, pp. 636–643, 2016.

[124] S. Shimada, M. Fukai, K. Wakayama et al., “Hydrogen sulfide augments survival signals in warm ischemia and reperfusion of the mouse liver,” Surgery Today, vol. 45, no. 7, pp. 892–903, 2015.

[125] F. P. Tu, J. X. Li, Q. Li, and J. Wang, “Effects of hydrogen sulfide on cognitive dysfunction and NR2B in rats,” The Journal of Surgical Research, vol. 205, no. 2, pp. 426–431, 2016.

[126] D. Wang, Y. Ma, Z. Li et al., “The role of AKT1 and autophagy in the protective effect of hydrogen sulfide against hepatic ischemia/reperfusion injury in mice,” Autophagy, vol. 8, no. 6, pp. 954–962, 2012.

[127] P. Cheng, F. Wang, K. Chen et al., “Hydrogen sulfide ameliorates ischemia/reperfusion-induced hepatitis by inhibiting apoptosis and autophagy pathways,” Mediators of Inflammation, vol. 2014, Article ID 935251, 16 pages, 2014.

[128] Y. Chen, Z. Liu, and X. Xie, “Hydrogen sulphide attenuates renal and cardiac injury after total hepatic ischemia and reperfusion,” The Journal of Surgical Research, vol. 164, no. 2, pp. e305–e313, 2010.

[129] N. N. Younis, M. A. Shaheen, and M. F. Mahmoud, “Silimar pre-conditioning protected insulin resistant rats from liver ischemia-reperfusion injury: role of endogenous H2S,” The Journal of Surgical Research, vol. 204, no. 2, pp. 398–409, 2016.

[130] Y. Chen, L. Zhao, S. Jiang et al., “Cystathionine γ-Lysase is involved in the renoprotective effect of brief and repeated ischemic postconditioning after renal ischemia/reperfusion injury in diabetes mellitus,” Transplantation Proceedings, vol. 50, no. 5, pp. 1549–1557, 2018.

[131] Z. M. Younossi, A. B. Koenig, D. Abdelatif, Y. Fazel, L. Henry, and M. Wymer, “Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes,” Hepatology, vol. 64, no. 1, pp. 73–84, 2016.

[132] M. A. Konerman, J. C. Jones, and S. A. Harrison, “Pharmacotherapy for NASH: current and emerging,” Journal of Hepatology, vol. 68, no. 2, pp. 362–375, 2018.

[133] N. Chalasani, Z. Younossi, J. E. Lavine et al., “The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association,” The American Journal of Gastroenterology, vol. 107, no. 6, pp. 811–826, 2012.

[134] H. Yki-Järvinen, “Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome,” The Lancet Diabetes and Endocrinology, vol. 2, no. 11, pp. 901–910, 2014.

[135] S. Schuster, D. Cabrera, M. Arrese, and A. E. Feldstein, “Triggering and resolution of inflammation in NASH,” Nature Reviews. Gastroenterology & Hepatology, vol. 15, no. 6, pp. 349–364, 2018.

[136] H. Yamada, N. Akahoshi, S. Kamata et al., “Methionine excess in diet induces acute lethal hepatitis in mice lacking cystathionine γ-lyase, an animal model of cystathioninuria,” Free Radical Biology & Medicine, vol. 52, no. 9, pp. 1716–1726, 2012.

[137] M. Li, C. Xu, J. Shi et al., “Fatty acids promote fatty liver disease via the dysregulation of 3-mercaptopyruvate sulfur-transferase/hydrogen sulfide pathway,” Gut, vol. 67, no. 12, pp. 2169–2180, 2018.

[138] L. Sun, S. Zhang, C. Yu et al., “Hydrogen sulfide reduces serum triglyceride by activating liver autophagy via the AMPK-mTOR pathway,” American Journal of Physiology-Endocrinology and Metabolism, vol. 309, no. 11, pp. E925–E935, 2015.

[139] P. Cheng, K. Chen, Y. Xia et al., “Hydrogen sulfide, a potential novel drug, attenuates concanavalin A-induced hepatitis,” Drug Design, Development and Therapy, vol. 8, pp. 1277–1286, 2014.

[140] Y.-c. Yu, Y.-m. Mao, C.-w. Chen et al., “CSH guidelines for the diagnosis and treatment of drug-induced liver injury,” Hepatology International, vol. 11, no. 3, pp. 221–241, 2017.

[141] Y. Gao, S. Chu, Q. Shao et al., “Antioxidant activities of ginsenoside Rg1 against cisplatin-induced hepatic injury
through Nrf2 signaling pathway in mice,” *Free Radical Research*, vol. 51, no. 1, pp. 1–13, 2017.

[142] P. Zhao, B. Liu, C. Wang, and Acute Liver Failure Study Team (ALFST), “Hepatotoxicity evaluation of traditional Chinese medicines using a computational molecular model,” *Clinical Toxicology*, vol. 55, no. 9, pp. 996–1000, 2017.

[143] S. H. Huang, C. W. Tung, F. Fülöp, and J. H. Li, “Developing a QSAR model for hepatotoxicity screening of the active compounds in traditional Chinese medicines,” *Food and Chemical Toxicology*, vol. 78, pp. 71–77, 2015.

[144] R. Teschke, A. Wolff, C. Frenzel, and J. Schulze, “Review article: herbal hepatotoxicity—an update on traditional Chinese medicine preparations,” *Alimentary Pharmacology & Therapeutics*, vol. 40, no. 1, pp. 32–50, 2014.

[145] J. Jing and R. Teschke, “Traditional Chinese medicine and herb-induced liver injury: comparison with drug-induced liver injury,” *Journal of Clinical and Translational Hepatology*, vol. 6, no. 1, pp. 57–68, 2018.

[146] T. J. Davenport and N. Chalasani, “Drug-induced liver injury in clinical trials: as rare as hens’ teeth,” *The American Journal of Gastroenterology*, vol. 104, no. 5, pp. 1159–1161, 2009.

[147] N. P. Chalasani, P. H. Hayashi, H. L. Bonkovsky, V. J. Navarro, W. M. Lee, and FACC & Robert J Fontana MD on behalf of the Practice Parameters Committee of the American College of Gastroenterology, “ACG clinical guideline: the diagnosis and management of idiosyncratic drug-induced liver injury,” *The American Journal of Gastroenterology*, vol. 109, no. 7, pp. 950–966, 2014.

[148] E. S. Björnsson, O. M. Bergmann, H. K. Björnsson, R. B. Kvaran, and S. Olafsson, “Incidence, presentation, and outcomes in patients with drug-induced liver injury in the general population of Iceland,” *Gastroenterology*, vol. 144, no. 7, pp. 1419–1425.e3, 2013.

[149] K. Furuta, Y. Yoshida, S. Ogura et al., “Gab1 adaptor protein acts as a gatekeeper to balance hepatocyte death and proliferation during acetaminophen-induced liver injury in mice,” *Hepatology*, vol. 63, no. 4, pp. 1340–1355, 2016.

[150] M. A. Morsy, S. A. Ibrahim, S. A. Abdelwahab, M. Z. Zedan, and H. I. Elbitor, “Curative effects of hydrogen sulfide against acetaminophen-induced hepatotoxicity in mice,” *Life Sciences*, vol. 87, no. 23-26, pp. 692–698, 2010.

[151] I. Ishii, S. Kamata, Y. Hagiyas, Y. Abiko, T. Kasahara, and Y. Kumagai, “Protective effects of hydrogen sulfide anions against acetaminophen-induced hepatotoxicity in mice,” *The Journal of Toxicological Sciences*, vol. 40, no. 6, pp. 837–841, 2015.

[152] D. Yang, Q. Yuan, A. Balakrishnan et al., “Micro-RNA-125b-5p mimic inhibits acute liver failure,” *Nature Communications*, vol. 7, no. 1, article 19116, 2016.

[153] J. Karkhanis, E. C. Verna, M. S. Chang et al., “Steroid use in acute liver failure,” *Hepatology*, vol. 59, no. 2, pp. 612–621, 2014.

[154] M. R. McGill and H. Jaeschke, “Mechanistic biomarkers in acetaminophen-induced hepatotoxicity and acute liver failure: from preclinical models to patients,” *Expert Opinion on Drug Metabolism & Toxicology*, vol. 10, no. 7, pp. 1005–1017, 2014.

[155] A. Ahmad, N. Druzyna, and C. Szabo, “Cystathionine-γ-methylase deficient mice are protected against the development of multiorgan failure and exhibit reduced inflammatory response during burn,” *Burns*, vol. 43, no. 5, pp. 1021–1033, 2017.

[156] K. C. Lai, C. L. Kuo, H. C. Ho et al., “Diallyl sulfide, diallyl disulfide and diallyl trisulfide affect drug resistant gene expression in Colo 205 human colon cancer cells in vitro and in vivo,” *Phytomedicine*, vol. 19, no. 7, pp. 625–630, 2012.

[157] T. Zeng, F. F. Guo, C. L. Zhang et al., “The anti-fatty liver effects of garlic oil on acute ethanol-exposed mice,” *Chemico-Biological Interactions*, vol. 176, no. 2–3, pp. 234–242, 2008.

[158] I. C. Lee, S. H. Kim, H. S. Baek et al., “The involvement of Nrf2 in the protective effects of diallyl disulfide on carbon tetrachloride-induced hepatic oxidative damage and inflammatory response in rats,” *Food and Chemical Toxicology*, vol. 63, pp. 174–185, 2014.

[159] A. A. Shaaban and D. S. El-Agamy, “Cytoprotective effects of diallyl trisulfide against valproate-induced hepatotoxicity: new anticonvulsant strategy,” *Naunyn-Schmiedeberg’s Archives of Pharmacology*, vol. 390, no. 9, pp. 919–928, 2017.

[160] J. W. Ko, S. H. Park, N. R. Shin et al., “Protective effect and mechanism of action of diallyl disulfide against acetaminophen-induced acute hepatotoxicity,” *Food and Chemical Toxicology*, vol. 109, Part 1, pp. 28–37, 2017.

[161] Y. Zhang, F. Zhang, K. Wang et al., “Protective effect of allyl methyl disulfide on acetaminophen-induced hepatotoxicity in mice,” *Chemico-Biological Interactions*, vol. 249, pp. 71–77, 2016.

[162] N. C. Sumedha and S. Miltonprabu, “Diallyl trisulfide ameliorates arsenic-induced hepatotoxicity by abrogation of oxidative stress, inflammation, and apoptosis in rats,” *Human & Experimental Toxicology*, vol. 34, no. 5, pp. 506–525, 2015.

[163] I. C. Lee, S. H. Kim, H. S. Baek et al., “Protective effects of diallyl disulfide on carbon tetrachloride-induced hepatotoxicity through activation of Nrf2,” *Environmental Toxicology*, vol. 30, no. 5, pp. 538–548, 2015.

[164] S. Ansar and M. Iqbal, “Amelioration of ferric nitroltriacetate-induced hepatotoxicity in Wistar rats by diallylulfide,” *Human & Experimental Toxicology*, vol. 35, no. 3, pp. 259–266, 2016.

[165] Y. Yang, L. Jiang, S. Wang, T. Zeng, and K. Xie, “Diallyl trisulfide protects the liver against hepatotoxicity induced by isoniazid and rifampin in mice by reducing oxidative stress and activating Kupffer cells,” *Toxicology Research*, vol. 5, no. 3, pp. 954–962, 2016.

[166] T. Fukao, T. Hosono, S. Misawa, T. Seki, and T. Ariga, “Chemoprotective effect of diallyl trisulfide from garlic against carbon tetrachloride-induced acute liver injury of rats,” *BioFactors*, vol. 21, no. 1–4, pp. 171–174, 2004.

[167] T. Hosono-Fukao, T. Hosono, T. Seki, and T. Ariga, “Diallyl trisulfide protects rats from carbon tetrachloride-induced liver injury,” *The Journal of Nutrition*, vol. 139, no. 12, pp. 2252–2256, 2009.

[168] X. Zhu, F. Zhang, L. Zhou et al., “Diallyl trisulfide attenuates carbon tetrachloride-caused liver injury and fibrogenesis and reduces hepatic oxidative stress in rats,” *Naunyn-Schmiedeberg’s Archives of Pharmacology*, vol. 387, no. 5, pp. 445–455, 2014.

[169] L. Y. Chen, Q. Chen, Y. F. Cheng et al., “Diallyl trisulfide attenuates ethanol-induced hepatic steatosis by inhibiting oxidative stress and apoptosis,” *Biomedicine & Pharmacotherapy*, vol. 79, pp. 35–43, 2016.
[170] T. Zeng, C. L. Zhang, F. Y. Song et al., “The activation of HO-1/Nrf-2 contributes to the protective effects of diallyl disulfide (DADS) against ethanol-induced oxidative stress,” *Biochimica et Biophysica Acta (BBA) - General Subjects*, vol. 1830, no. 10, pp. 4848–4859, 2013.

[171] M. Li, S. Wang, X. Li et al., “Diallyl sulfide protects against lipopolysaccharide/d-galactosamine-induced acute liver injury by inhibiting oxidative stress, inflammation and apoptosis in mice,” *Food and Chemical Toxicology*, vol. 120, pp. 500–509, 2018.

[172] S. Ansar and M. Iqbal, “Protective effect of diallylsulphide against mercuric chloride-induced hepatic injury in rats,” *Human & Experimental Toxicology*, vol. 35, no. 12, pp. 1305–1311, 2016.

[173] C. C. Wu, J. G. Chung, S. J. Tsai, J. H. Yang, and L. Y. Sheen, “Differential effects of allyl sulfides from garlic essential oil on cell cycle regulation in human liver tumor cells,” *Food and Chemical Toxicology*, vol. 42, no. 12, pp. 1937–1947, 2004.

[174] S. S. Ibrahim and N. N. Nassar, “Diallyl sulfide protects against N-nitrosodiethylamine-induced liver tumorigenesis: role of aldose reductase,” *World Journal of Gastroenterology*, vol. 14, no. 40, pp. 6145–6153, 2008.

[175] J. Wen, Y. Zhang, X. Chen, L. Shen, G. C. Li, and M. Xu, “Enhancement of diallyl disulfide-induced apoptosis by inhibitors of MAPKs in human HepG2 hepatoma cells,” *Biochemical Pharmacology*, vol. 68, no. 2, pp. 323–331, 2004.

[176] M. Iciek, I. Kwiecień, G. Chwatko, M. Sokolowska-Jeżewicz, D. Kowalczyk-Pachel, and H. Rokita, “The effects of garlic-derived sulfur compounds on cell proliferation, caspase 3 activity, thiol levels and anaerobic sulfur metabolism in human hepatoblastoma HepG2 cells,” *Cell Biochemistry and Function*, vol. 30, no. 3, pp. 198–204, 2012.

[177] D. Guyonnet, R. Bergès, M. H. Siess et al., “Post-initiation modulating effects of allyl sulfides in rat hepatocarcinogenesis,” *Food and Chemical Toxicology*, vol. 42, no. 9, pp. 1479–1485, 2004.

[178] L. Yi and Q. Su, “Molecular mechanisms for the anti-cancer effects of diallyl disulfide,” *Food and Chemical Toxicology*, vol. 57, pp. 362–370, 2013.